Ake­bia shares MACEd as their PhI­II ane­mia drug fails on safe­ty, of­fer­ing ri­val Fi­bro­Gen a huge ad­van­tage

Ake­bia $AK­BA slammed di­rect­ly in­to an un­ex­pect­ed brick wall Thurs­day morn­ing, as the biotech re­port­ed a crit­i­cal fail­ure in its sec­ond Phase III study of its ane­mia drug vadadu­s­tat.

The drug hit the pri­ma­ry and key sec­on­daries for ef­fi­ca­cy in a late-stage study pit­ting the drug against the in­jectable ESA dar­be­po­et­in al­fa among chron­ic kid­ney dis­ease pa­tients not on dial­y­sis. But it failed on the all-im­por­tant MACE non-in­fe­ri­or­i­ty stan­dard for safe­ty, track­ing time to first oc­cur­rence of ma­jor ad­verse car­dio­vas­cu­lar events.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA